Y-MABS THERAPEUTICS INC
BiotechY-MABS THERAPEUTICS INC is a biotechnology company focused on Immunology, Oncology, Dermatology.
FDA Novel Drug Designations
(2020)See 1 novel approval →
Y-MABS THERAPEUTICS INC at a Glance
- Fast trial execution (11 months median completion)
Y-MABS THERAPEUTICS INC's Key Drugs
Y-MABS THERAPEUTICS INC's core commercial portfolio centers on DANYELZA, spanning Immunology and Oncology — its most strategically important drugs approved in the last 15 years.
Y-MABS THERAPEUTICS INC's Recent FDA Approvals
New NDA/BLA approvals for Y-MABS THERAPEUTICS INC over the last two years — novel drugs only, excluding generics and label supplements.
Y-MABS THERAPEUTICS INC's Therapeutic Areas
Y-MABS THERAPEUTICS INC's approved drugs and pipeline span 3 therapeutic areas, led by Immunology and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Y-MABS THERAPEUTICS INC's Top Competitors
Y-MABS THERAPEUTICS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and PF PRISM CV. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Y-MABS THERAPEUTICS INC Pipeline Snapshot
Y-MABS THERAPEUTICS INC has 21 active clinical programs from ClinicalTrials.gov — 7 Phase 3, 8 Phase 2 and 6 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/0 completed
- • Speed: 11 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2020-11-25
- Latest
- 2025-08-27
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges